Full Press Release Details
• Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026
ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.
Along with a clinical program overview, the event will feature perspectives from REGENXBIO management and leading retina specialists on the treatment landscape, unmet need, ATMOSPHERE ® and ASCENT ® pivotal trials, and commercial readiness of sura-vec in wet AMD.
Featured key opinion leaders include:
• Gaurav Shah, M.D., FASRS, California Pacific Medical Center, Sutter Health
• Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates
• Lejla Vajzovic, M.D., FASRS, Duke University School of Medicine
• Rahul Khurana, M.D., FASRS, Northern California Retina Vitreous Associates, University of California at San Francisco
• Ramanath Bhandari, M.D., FASRS, Springfield Clinic Eye Institute
Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives Date: Tuesday, October 20, 2026 Time: 1:00 p.m. ET – 4:00 p.m. ET Location: New York, NY and Virtual Registration for the webcast is available at this LINK.
An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the event.
ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA ® and ITVISMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.